HeartSciences Inc.
For the period ended Apr 30, 2026. Filed Jul 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jul 23, 2026
HSCS$2.40-11.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of April 30, 2026 and 2025
Balance Sheets
| April 30, | ||
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $1,656,814 | $1,098,098 |
| Accounts receivable | — | 4,350 |
| Inventory, net | 655,629 | 650,267 |
| Prepaid expenses | 83,049 | 87,443 |
| Other current assets | 40,374 | 40,374 |
| Deferred offering costs | 147,062 | 290,925 |
| Total current assets | 2,582,928 | 2,171,457 |
| Property and equipment, net | 39,312 | 63,549 |
| Capitalized software | 715,191 | — |
| Intangible assets, net | 1,657,175 | 1,616,277 |
| Right-of-use assets, net | 268,067 | 371,626 |
| TOTAL ASSETS | $5,262,673 | $4,222,909 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $318,327 | $318,661 |
| Accrued expenses | 432,454 | 506,307 |
| Accrued interest expense | 327,960 | 177,628 |
| Operating lease liabilities, current portion | 139,026 | 119,518 |
| Notes payable | 3,622,120 | 2,551,170 |
| Other current liabilities | 21,225 | 29,927 |
| Total current liabilities | 4,861,112 | 3,703,211 |
| LONG-TERM LIABILITIES | ||
| Operating lease liabilities, long-term portion | 175,501 | 314,527 |
| Total long-term liabilities | 175,501 | 314,527 |
| TOTAL LIABILITIES | 5,036,613 | 4,017,738 |
| COMMITMENTS AND CONTINGENCIES (NOTE 2, 4-6, and 8) | ||
| STOCKHOLDERS' EQUITY | ||
| Series C convertible preferred stock, $0.001 par value, 20,000,000 shares authorized and 600,000 designated; 380,440 shares issued and outstanding as of April 30, 2026 and 2025. | 380 | 380 |
| Series D convertible preferred stock, $0.001 par value, 20,000,000 shares authorized and 4,285,714 designated; 532,594 shares issued and outstanding as of April 30, 2026 and 0 shares issued and outstanding as of April 30, 2025. | 533 | — |
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 3,188,380 shares issued and outstanding as of April 30, 2026 and 1,119,107 shares issued and outstanding as of April 30, 2025. | 3,188 | 1,119 |
| Additional paid-in capital | 85,491,469 | 76,331,307 |
| Accumulated deficit | (85,269,510) | (76,127,635) |
| TOTAL STOCKHOLDERS' EQUITY | 226,060 | 205,171 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $5,262,673 | $4,222,909 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.